Characterizing pharmacogenetic programs using the consolidated framework for implementation research: A structured scoping review
Several healthcare organizations have developed pre-emptive pharmacogenetic testing programs, where testing is undertaken prior to the prescription of a medicine. This review characterizes the barriers and facilitators which influenced the development of these programs. A bidirectional citation sear...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.945352/full |
| _version_ | 1811214706954731520 |
|---|---|
| author | John H. McDermott John H. McDermott Stuart Wright Videha Sharma William G. Newman William G. Newman Katherine Payne Paul Wilson |
| author_facet | John H. McDermott John H. McDermott Stuart Wright Videha Sharma William G. Newman William G. Newman Katherine Payne Paul Wilson |
| author_sort | John H. McDermott |
| collection | DOAJ |
| description | Several healthcare organizations have developed pre-emptive pharmacogenetic testing programs, where testing is undertaken prior to the prescription of a medicine. This review characterizes the barriers and facilitators which influenced the development of these programs. A bidirectional citation searching strategy identified relevant publications before a standardized data extraction approach was applied. Publications were grouped by program and data synthesis was undertaken using the Consolidated Framework for Implementation Research (CFIR). 104 publications were identified from 40 programs and 4 multi-center initiatives. 26 (66%) of the programs were based in the United States and 95% in high-income countries. The programs were heterogeneous in their design and scale. The Characteristics of the Intervention, Inner Setting, and Process domains were referenced by 92.5, 80, and 77.5% of programs, respectively. A positive institutional culture, leadership engagement, engaging stakeholders, and the use of clinical champions were frequently described as facilitators to implementation. Clinician self-efficacy, lack of stakeholder knowledge, and the cost of the intervention were commonly cited barriers. Despite variation between the programs, there were several similarities in approach which could be categorized via the CFIR. These form a resource for organizations planning the development of pharmacogenetic programs, highlighting key facilitators which can be leveraged to promote successful implementation. |
| first_indexed | 2024-04-12T06:09:13Z |
| format | Article |
| id | doaj.art-3b1efa8fe9c74ad08f55d7f1691342b9 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-12T06:09:13Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-3b1efa8fe9c74ad08f55d7f1691342b92022-12-22T03:44:46ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-08-01910.3389/fmed.2022.945352945352Characterizing pharmacogenetic programs using the consolidated framework for implementation research: A structured scoping reviewJohn H. McDermott0John H. McDermott1Stuart Wright2Videha Sharma3William G. Newman4William G. Newman5Katherine Payne6Paul Wilson7Manchester Centre for Genomic Medicine, St Mary’s Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, United KingdomDivision of Evolution, Infection and Genomics, School of Biological Sciences, The University of Manchester, Manchester, United KingdomDivision of Population Health, Manchester Centre for Health Economics, Health Services Research and Primary Care, School of Health Sciences, The University of Manchester, Manchester, United KingdomDivision of Informatics, Centre for Health Informatics, Imaging and Data Science, School of Health Sciences, The University of Manchester, Manchester, United KingdomManchester Centre for Genomic Medicine, St Mary’s Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, United KingdomDivision of Evolution, Infection and Genomics, School of Biological Sciences, The University of Manchester, Manchester, United KingdomDivision of Population Health, Manchester Centre for Health Economics, Health Services Research and Primary Care, School of Health Sciences, The University of Manchester, Manchester, United KingdomDivision of Population Health, Centre for Primary Care and Health Services Research, Health Services Research and Primary Care, School of Health Sciences, The University of Manchester, Manchester, United KingdomSeveral healthcare organizations have developed pre-emptive pharmacogenetic testing programs, where testing is undertaken prior to the prescription of a medicine. This review characterizes the barriers and facilitators which influenced the development of these programs. A bidirectional citation searching strategy identified relevant publications before a standardized data extraction approach was applied. Publications were grouped by program and data synthesis was undertaken using the Consolidated Framework for Implementation Research (CFIR). 104 publications were identified from 40 programs and 4 multi-center initiatives. 26 (66%) of the programs were based in the United States and 95% in high-income countries. The programs were heterogeneous in their design and scale. The Characteristics of the Intervention, Inner Setting, and Process domains were referenced by 92.5, 80, and 77.5% of programs, respectively. A positive institutional culture, leadership engagement, engaging stakeholders, and the use of clinical champions were frequently described as facilitators to implementation. Clinician self-efficacy, lack of stakeholder knowledge, and the cost of the intervention were commonly cited barriers. Despite variation between the programs, there were several similarities in approach which could be categorized via the CFIR. These form a resource for organizations planning the development of pharmacogenetic programs, highlighting key facilitators which can be leveraged to promote successful implementation.https://www.frontiersin.org/articles/10.3389/fmed.2022.945352/fullpharmacogeneticsprecision medicineimplementation sciencemedical informaticspharmacogenomics |
| spellingShingle | John H. McDermott John H. McDermott Stuart Wright Videha Sharma William G. Newman William G. Newman Katherine Payne Paul Wilson Characterizing pharmacogenetic programs using the consolidated framework for implementation research: A structured scoping review Frontiers in Medicine pharmacogenetics precision medicine implementation science medical informatics pharmacogenomics |
| title | Characterizing pharmacogenetic programs using the consolidated framework for implementation research: A structured scoping review |
| title_full | Characterizing pharmacogenetic programs using the consolidated framework for implementation research: A structured scoping review |
| title_fullStr | Characterizing pharmacogenetic programs using the consolidated framework for implementation research: A structured scoping review |
| title_full_unstemmed | Characterizing pharmacogenetic programs using the consolidated framework for implementation research: A structured scoping review |
| title_short | Characterizing pharmacogenetic programs using the consolidated framework for implementation research: A structured scoping review |
| title_sort | characterizing pharmacogenetic programs using the consolidated framework for implementation research a structured scoping review |
| topic | pharmacogenetics precision medicine implementation science medical informatics pharmacogenomics |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.945352/full |
| work_keys_str_mv | AT johnhmcdermott characterizingpharmacogeneticprogramsusingtheconsolidatedframeworkforimplementationresearchastructuredscopingreview AT johnhmcdermott characterizingpharmacogeneticprogramsusingtheconsolidatedframeworkforimplementationresearchastructuredscopingreview AT stuartwright characterizingpharmacogeneticprogramsusingtheconsolidatedframeworkforimplementationresearchastructuredscopingreview AT videhasharma characterizingpharmacogeneticprogramsusingtheconsolidatedframeworkforimplementationresearchastructuredscopingreview AT williamgnewman characterizingpharmacogeneticprogramsusingtheconsolidatedframeworkforimplementationresearchastructuredscopingreview AT williamgnewman characterizingpharmacogeneticprogramsusingtheconsolidatedframeworkforimplementationresearchastructuredscopingreview AT katherinepayne characterizingpharmacogeneticprogramsusingtheconsolidatedframeworkforimplementationresearchastructuredscopingreview AT paulwilson characterizingpharmacogeneticprogramsusingtheconsolidatedframeworkforimplementationresearchastructuredscopingreview |